L26/P-907 An expedited protocol to generate competent de novo spermatozoa for proven azoospermic men
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1231 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von P. Xie und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Can we offer a chance to procreate for truly azoospermic men by generating neogametes in vitro in a simple and expedited manner? Summary answer We were able to generate euploid human embryos utilizing de novo spermatozoa differentiated from male stem cells cultured in a novel 3D system. What is known already ICSI enables fertilization using a single spermatozoon, including surgically retrieved testicular spermatozoa. However, men with complete spermatogenic arrest or germ cell aplasia remain untreatable. Prior efforts to generate male gametes from stem cells required xenogeneic or allogeneic transplantation to complete spermiogenesis, raising safety, ethical, and translational concerns. We aim to generate competent neogametes by reproducing spermatogenesis in a novel 3D culture system starting from human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs). Study design, size, duration Male hESCs and hiPSCs were encapsulated in calcium alginate spheres and cultured up to 70 days to mimic physiological spermatogenesis of human. Spermatogenesis was coaxed by serial media containing various growth factors. Germ cell differentiation was assessed using stage-specific markers. Cytogenetic was performed to assess gamete ploidy. Differentiated neogametes were injected into donated oocytes and activated. Mature spermatozoa were used as control. Embryo development was monitored to the blastocyst to assess ploidy. Participants/materials, setting, methods Germ cell differentiation was assessed using stage-specific markers: OCT4 (pluripotency), GFRA1 (spermatogonia), VASA (primary spermatocyte), BOULE (secondary spermatocyte), and ACROSIN (spermatid). The ploidy of neogametes was evaluated by FISH. Haploid cells were introduced into oocytes by a modified somatic cell nuclear transfer technique, followed by a tailored protocol of assisted oocyte activation using recombinant human PLCζ and calcium ionophore. Embryo development was monitored by time-lapse microscopy, and resulting blastocysts underwent PGT-A. Main results and the role of chance In hESCs, loss of pluripotency was evident by day 7, with OCT4 declining from 93.6% to 8.4%. Concurrent spermatogonial emergence was observed at 31% on day 14. Spermatogenic progression, assessed by VASA, plateaued at 45.1% on day 21 and remained stable. Meiosis, demonstrated by BOULE expression, appeared on day 21 and reached 38.9% by day 49. Post-meiotic assessment by FISH confirmed 56.0% haploidy, of which 12.9% expressed acrosin on day 56. A similar pattern was observed with hiPSCs, with pluripotency decreasing from 91.8% to 15.2% by day 7. Concurrent spermatogonial differentiation was observed at 26.0% by GFRA1 expression. Spermatocyte markers reached 50.6% on day 21 and declined to 33.3% by day 56. Meiosis occurred by day 14, with BOULE peaking at 47.7% on day 56. Cytogenetic analysis showed 25.0% haploidy, of which 11.1% expressed acrosin. Donor sperm controls achieved 67% (2/3) fertilization and 100% (2/2) blastulation. The hESC-derived neogametes yielded 31.6% (6/19) fertilization and 100% (6/6) cleavage and reached the morula stage (n = 3). The hiPSC-derived neogametes achieved 35.7% (5/14) fertilization, 100% (5/5) cleavage, and 60% (3/5) blastulation, albeit with delayed morphokinesis. Morula/blastocysts from both hESC and hiPSC experiments revealed 33% euploidy (1 morula from hESCs and 1 blastocyst from hiPSCs). Limitations, reasons for caution We were able to recreate in vitro human spermatogenesis, maintaining the same timing at approximately 56–70 days in our 3D niche. Despite the incomplete spermiogenesis, our neogametes were able to sustain full pre-implantation development, albeit at a lower rate. A larger study will confirm the outcome. Wider implications of the findings This fully in vitro model represents a reproductive option toward genotyped gametes for men with untreatable azoospermia, eliminating the need for xenogeneic transplantation. The modification of the insemination method obviate the need for spermiogenesis. Isolated somatic cells from untreatable infertile men can be used to generate male gametes. Trial registration number No
Zitieren
APA
Xie, P., Cheung, S., Ng, L., Jesus, A. D., Rosenwaks, Z., & Palermo, G. (2026). L26/P-907 An expedited protocol to generate competent de novo spermatozoa for proven azoospermic men. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1231
Vancouver
Xie P, Cheung S, Ng L, Jesus AD, Rosenwaks Z, Palermo G. L26/P-907 An expedited protocol to generate competent de novo spermatozoa for proven azoospermic men. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1231
BibTeX
@article{Xie2026,
author = {Xie, P. and Cheung, S. and Ng, L. and Jesus, A. De and Rosenwaks, Z. and Palermo, G.D.},
title = {L26/P-907 An expedited protocol to generate competent de novo spermatozoa for proven azoospermic men},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1231}
}
EUVIMED